Catatonia Breakthrough: How Acamprosate Offers Hope When ECT Falls Short
"Exploring a novel treatment approach for catatonia in frontotemporal dementia (FTD) using acamprosate to sustain recovery after initial ECT response."
Frontotemporal dementia (FTD), often representing 10-15% of dementia cases, poses significant challenges in diagnosis and treatment. As the third most prevalent neurodegenerative cortical dementia, following Alzheimer's and Lewy body dementia, FTD equally affects men and women, typically between 45 and 65 years old. Its early symptoms involve subtle behavioral and personality changes, which can be difficult to distinguish from other psychiatric conditions.
Catatonia, characterized by a range of motor and behavioral disturbances, frequently complicates the presentation of dementia, including FTD. Diagnosing catatonia in dementia patients can be challenging due to overlapping symptoms, often leading to underdiagnosis. While treatments like lorazepam and electroconvulsive therapy (ECT) are typically effective, their benefits can be short-lived or accompanied by significant side effects, necessitating alternative strategies.
Recent research highlights the potential of acamprosate, a medication primarily used to treat alcoholism, in managing catatonia associated with FTD. A case study demonstrated that acamprosate effectively sustained recovery in a patient with catatonic FTD after initial ECT response waned. This article explores this innovative treatment approach, offering hope for improved management of complex neuropsychiatric cases.
Catatonia and Dementia: Prevalence and Treatment Burden
A descriptive study conducted between 2015 and 2022 found that 25 out of 143 patients treated for catatonia in a specialized psychiatry department had a comorbid dementia diagnosis, highlighting a notable overlap between the two conditions. Recent systematic review data indicate that catatonia occurring in the context of dementia is associated with a lower rate of complete therapeutic response and a greater reliance on alternative or adjunctive therapies compared to catatonia in older adults without dementia. Catatonia remains underdiagnosed in geriatric patients with dementia despite the existence of established diagnostic criteria and treatment options, suggesting that the true burden of this condition may be significantly underestimated in clinical practice.
Diagnosis and Treatment Challenges in Dementia-Related Catatonia
Catatonia is a neuropsychiatric syndrome characterized by motor, behavioral, and autonomic abnormalities that is often underdiagnosed in geriatric patients with dementia, even though established diagnostic criteria and treatment options exist. Research indicates that the presence of dementia influences treatment choices for catatonia and appears to be a predictor of a poorer therapeutic response, complicating clinical management. In documented cases of behavioral frontotemporal dementia presenting with catatonia, drug treatment has been investigated using advanced neuroimaging techniques such as PET/MRI to track brain functional modifications, illustrating the complexity of identifying and managing this overlap clinically.
The Long History of Catatonia Before Formal Recognition
The history of catatonic symptoms began long before Kahlbaum formalized the concept, with numerous German- and English-speaking authors having described typical catatonic features such as melancholia attonita, catalepsy, stereotypies, mannerisms, negativism, and stupor. These early observers, however, did not consider these presentations to constitute a distinct syndrome, meaning the clinical recognition of catatonia evolved slowly over many decades. Today, despite its established diagnostic criteria, catatonia continues to be underdiagnosed in older adults and those with dementia, echoing a pattern of clinical oversight that has persisted since its earliest documented descriptions.
Acamprosate: A Novel Approach to Sustaining Catatonia Relief
Catatonia's underlying neurobiology points to cortical GABA deficiency and glutamate excitotoxicity. This understanding has led to the use of benzodiazepines and ECT as primary treatments, irrespective of the cause. However, clinicians often hesitate to use these "aggressive" methods on frail, demented patients due to potential side effects and concerns about tolerability.
- GABA Deficiency: Catatonia often involves reduced levels of GABA, an inhibitory neurotransmitter in the brain.
- Glutamate Excitotoxicity: Excessive glutamate activity can lead to neuronal damage and contribute to catatonic symptoms.
- Acamprosate Mechanism: By modulating GABA and glutamate, acamprosate helps restore balance in brain activity.
- ECT Limitations: While effective, ECT's benefits can be temporary, and it may have cognitive side effects.
- Safety Profile: Acamprosate is generally well-tolerated, with fewer risks for elderly patients compared to other treatments.
Advances in Catatonia Diagnosis and Emerging Treatments
A comprehensive review published in 2025 underscores the importance of early diagnosis and timely intervention in catatonia, highlighting that delays in recognition can worsen patient outcomes. Advances in neuroimaging have enhanced the ability to identify neurobiological correlates of catatonic states, providing clinicians with more objective tools to supplement clinical assessment. Novel therapeutic options have also expanded the treatment landscape for catatonia, opening new directions for both research and clinical practice beyond traditional approaches.
When Standard Treatments Reveal Deeper Complexity
Catatonia occurring as part of a clinical picture of dementia has been reported with almost all types of dementia, yet it remains under-diagnosed in older adults and those with cognitive impairment. In one documented case, a young patient admitted for catatonia responded efficiently to Lorazepam treatment, but subsequent assessment revealed an underlying dementia — demonstrating how standard benzodiazepine treatment can mask a more complex underlying condition. In another case, after symptomatic treatment of catatonia with benzodiazepines, assessment revealed an aphaso-apraxo-agnotic syndrome with memory dysfunctions including amnesia with false recognition and executive dysfunction, underscoring the diagnostic pitfalls clinicians face.
Differential Responses Across Catatonia Presentations in Dementia
Research on catatonia in dementia patients suggests that different catatonic symptoms may show differential responses to therapeutic agents, meaning that a one-size-fits-all treatment approach is unlikely to succeed. When verbal symptoms are dominant, clinicians have found it worthwhile to try zolpidem in the early stage as an alternative to first-line benzodiazepines. A significant diagnostic challenge exists in differentiating the behavioral variant of frontotemporal dementia from catatonia, as the two conditions share overlapping motor symptoms including stupor, creating a complex neuropsychiatric diagnostic puzzle.
The Future of Catatonia Treatment
The successful use of acamprosate in this case opens new possibilities for catatonia treatment, especially for patients who do not respond well to first-line treatments or cannot tolerate their side effects. More research is needed through well-designed clinical trials to fully understand the potential of acamprosate in catatonia management and to refine treatment protocols. This case offers a promising step forward in improving the care and quality of life for individuals with catatonic FTD.
What the Evidence Tells Us — And What It Doesn't
The growing body of literature on catatonia in dementia paints a picture of a condition that is both more common than historically recognized and more difficult to treat than catatonia in cognitively intact patients. While benzodiazepines remain a frontline intervention, their efficacy in dementia-associated catatonia appears diminished, and the search for effective alternatives — including agents like acamprosate — represents a promising but still-emerging frontier. Clinicians working at the intersection of neuropsychiatry and geriatric medicine are increasingly recognizing that catatonia demands its own dedicated diagnostic attention rather than being dismissed as a symptom of the underlying dementia.
Where Catatonia Research Is Heading
Neuroimaging advances are likely to play an increasingly central role in both diagnosing catatonia and monitoring treatment response, potentially allowing clinicians to identify patients who would benefit from alternative therapies earlier in the course of illness. The exploration of novel pharmacological agents beyond benzodiazepines and ECT remains in its early stages, but the expanding understanding of catatonia's neurobiological underpinnings may reveal new therapeutic targets. Larger, well-controlled studies specifically focused on catatonia in dementia populations are critically needed, as much of the current evidence base relies on case reports and small descriptive studies.
Systemic Barriers to Better Catatonia Care
Despite established diagnostic criteria, catatonia continues to be systematically underdiagnosed in older adults with dementia, pointing to significant gaps in clinical training and awareness across geriatric and psychiatric care settings. The overlap between catatonic symptoms and the behavioral manifestations of dementia creates genuine diagnostic ambiguity that current clinical tools struggle to resolve with confidence. Addressing these challenges will likely require not only better diagnostic frameworks but also interdisciplinary collaboration between neurologists, psychiatrists, and geriatricians to ensure that catatonia is identified and treated appropriately in this vulnerable population.
Living at the Intersection of Catatonia and Dementia
For patients and families, the underdiagnosis of catatonia in dementia means that treatable symptoms may go unrecognized, prolonging suffering and reducing quality of life unnecessarily. When standard treatments like ECT or benzodiazepines fail to produce expected responses in these patients, the emotional and financial toll on caregiving families can be substantial, compounded by the uncertainty of not understanding why conventional approaches are falling short. The development of alternative therapeutic options offers genuine hope, but translating research advances into routine clinical practice remains an ongoing challenge that directly affects patients navigating this difficult intersection of conditions.